Device Week, 12 Feb. 2020 – A Close-Up On AbioMed’s Plan to Counter Unfavorable Impella Data.

In this edition of Device Week, Medtech Insight's managing editor Marion Webb talks with deputy editor Reed Miller about his recent story on Abiomed's plan to counter unfavorable study outcomes of its Impella heart pump. Medtech Insight articles addressing topics discussed in this episode: AbioMed Launches Plan To Counter Unfavorable Impella Data https://medtech.pharmaintelligence.informa.com/MT126227/Abiomed-Launches-$100M-Plan-To-Counter-Unfavorable-Impella-Data Start-Up Spotlight: BioIntelliSense Launches New FDA-Cleared BioSticker For Remote Monitoring Of Patients' Vital Signs https://medtech.pharmaintelligence.informa.com/MT126231/StartUp-Spotlight-BioIntelliSense-Launches-New-FDACleared-BioSticker-For-Remote-Monitoring-Of-Patien Knees Boost Zimmer Biomet; Turnaround Continues, But FDA Woes Linger https://medtech.pharmaintelligence.informa.com/MT126216/Knees-Boost-Zimmer-Biomet-Turnaround-Continues-But-FDA-Woes-Linger Boston Scientific Expects Up to $40M Impact In Q1 From Coronavirus Outbreak; 10%-12% Revenue Increase For 2020 https://medtech.pharmaintelligence.informa.com/MT126214/Boston-Scientific-Expects-Up-To-40M-Impact-In-Q1-From-Coronavirus-Outbreak-1012-Revenue-Increase-For For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR